- Home
- COYA vs FHTX Comparison
COYA vs FHTX Comparison
Compare COYA & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COYA | FHTX |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.7M | 111.1M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | COYA | FHTX |
|---|---|---|
| Price | $3.24 | $2.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $15.21 | $4.17 |
| AVG Volume (30 Days) | 166.4K | ★ 679.3K |
| Earning Date | 11-10-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.32 |
| EPS | N/A | ★ 0.43 |
| Revenue | $7,945,753.00 | ★ $30,909,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $335.89 | N/A |
| P/E Ratio | ★ N/A | $4.83 |
| Revenue Growth | ★ 123.57 | 36.75 |
| 52 Week Low | $2.72 | $1.79 |
| 52 Week High | $6.62 | $7.61 |
Technical Indicators
Market Signals| Indicator | COYA | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.25 | 37.86 |
| Support Level | N/A | $1.79 |
| Resistance Level | $5.17 | $2.28 |
| Average True Range (ATR) | 0.35 | 0.16 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 32.91 | 41.24 |
Price Performance
Historical ComparisonAbout COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
About FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.